COVID-19 vaccination in patients with cancer (with Narjust Duma)
We speak to medical oncologist Narjust Duma, from the University of Wisconsin in the USA, about COVID-19 vaccination in people with cancer, discussing issues such as vaccine timing, side-effects, and key unanswered research questions.
27 May 2020
Conducting cancer clinical trials in the COVID-19 era (with Gary Lyman)
In this Medicine Matters oncology podcast, we speak to Gary Lyman (Fred Hutchinson Cancer Research Center and the University of Washington, Seattle, USA) about the impact of the COVID-19 outbreak on the conduct of cancer clinical trials.
Find more on Medicine Matters oncology (https://bit.ly/Lyman-COVID-19-podcast)
22 May 2020
The UK Coronavirus Cancer Monitoring Project: What you need to know (with Lennard Lee)
Co-project leader Lennard Lee talks about the inception and development of the initiative that will provide insight into the impact of COVID-19 on people with cancer and facilitate shared learning that will benefit patient care.
Find more on Medicine Matters oncology (https://bit.ly/Lee-COVID-19-podcast)
8 Apr 2020
CCC19: Introducing The COVID-19 and Cancer Consortium (with Gilberto Lopes)
Managing patients with genitourinary cancers in the time of COVID-19 (with Cora Sternberg)
Genitourinary oncologists Cora Sternberg (Weill Cornell Medicine, New York, USA) and Axel Merseburger (University Hospital Schleswig-Holstein, Lübeck, Germany) share their experience of managing cancer patients during the COVID-19 pandemic, comparing perspectives from a US and German stand point.
Find more on Medicine Matters oncology (http://bit.ly/Sternberg-COVID-19-podcast)
17 Mar 2020
COVID-19 and cancer patient care: A lung cancer specialist’s experience (with Gilberto Lopes)
Gilberto Lopes discusses the impact of the COVID-19 pandemic on the management of patients with lung cancer and outlines the measures being implemented to minimize the risk for patients.
Find more on Medicine Matters oncology
7 Oct 2019
Expert comment: AMG 510 KRAS inhibitor trial results – ‘A good start’ (with Colin Lindsay)
Colin Lindsay discusses the trial results for AMG 510 – a novel inhibitor targeting the KRAS G12C mutation – in patients with locally advanced or metastatic non-small-cell lung cancer.
Find more on Medicine Matters oncology (http://bit.ly/Lindsay-podcast-WCLC-2019)
More from WCLC 2019 (http://bit.ly/WCLC-2019-coverage)
24 Jun 2019
Understanding the relationship between the gut microbiome and immunotherapy (with Jennifer Wargo)
Recent research has shown an association between intestinal microbiota and response to immunotherapy in the setting of various tumor types. Listen to Jennifer Wargo, from The University of Texas MD Anderson Cancer Center in Houston, USA, share her insights into the findings.
Find more on Medicine Matters oncology (http://bit.ly/Wargo-Gut-microbiome-immunotherapy)
This content was originally published on Medicine Matters oncology (https://oncology.medicinematters.com/) on January 28, 2019.
24 Jun 2019
Researcher comment: COMPARE study (with Hashim Ahmed)
Hashim Ahmed takes us through the COMPARE study – presented at NCRI 2018 – which showed that men with localized prostate cancer are willing to accept lower survival odds for a better quality of life. He outlines the key findings, the implications of the results for physicians, and the next steps for research.
Find more on Medicine Matters oncology
This content was originally published on Medicine Matters oncology (https://oncology.medicinematters.com/ (https://oncology.medicinematters.com/)) on November 15, 2018.
24 Jun 2019
ALL and infection: Unpicking the connection (with Mel Greaves)
Professor Mel Greaves (Institute of Cancer Research, London, UK) discusses his proposed theory for the etiology of childhood acute lymphoblastic leukemia, in which early microbial exposure plays a key role. He outlines the evidence supporting the hypothesis and delves into the implications.
Find more on Medicine Matters oncology
This content was originally published on Medicine Matters oncology (https://oncology.medicinematters.com/ (https://oncology.medicinematters.com/)) on October 15, 2018.
24 Jun 2019
SUMIT: Selumetinib in metastatic uveal melanoma (with Paul Nathan)
Advisory Board member and study author Paul Nathan, from the Mount Vernon Cancer Centre in Middlesex, UK, discusses the phase III SUMIT trial, which evaluated the addition of the MEK inhibitor selumetinib to dacarbazine in patients with metastatic uveal melanoma.
Find more on Medicine Matters oncology
This content was originally published on Medicine Matters oncology (https://oncology.medicinematters.com/ (https://oncology.medicinematters.com/)) on May 4, 2018.
In this podcast, Fabien Maldonado, from Vanderbilt University Medical Center in Nashville, Tennessee, USA, provides an independent comment on the AMPLE trial, published in JAMA, which aimed to establish the more effective technique for reducing the number of hospitalization days in patients with malignant pleural effusion.
Find more on Medicine Matters oncology
This content was originally published on Medicine Matters oncology (https://oncology.medicinematters.com/ (https://oncology.medicinematters.com/)) on January 2, 2018.
24 Jun 2019
Bevacizumab in cervical cancer (with Krishnansu Tewari)
The phase III GOG 240 trial evaluated bevacizumab in women with advanced cervical cancer - Advisory Board member and lead investigator Krishnansu Tewari outlines the results of the final analysis in this podcast.
Find more on Medicine Matters oncology
This content was originally published on Medicine Matters oncology (https://oncology.medicinematters.com/) on December 12, 2017.
Reach and audience
Public platform figures. Ratings count people who left a rating, not total listeners.
Apple Podcasts (US)
2.0 / 5
1 ratings
Contact Medicine Matters oncology
Guest appearances
Books guests
Based on episode analysis; this does not confirm that the show is currently accepting guests.
Host of Medicine Matters oncology?
Claim your podcast to manage its listing and keep your show details accurate.
Pod Engine is an independent podcast discovery and analytics service and is not affiliated with or endorsed by this podcast. Artwork and show content belong to their owners. Full legal notice.
Explore this show Podcast research with Pod Engine
